Cadila Healthcare - ‘Virafin’ Approval Bodes Well To Tackle Rising Covid-19 Cases: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Cadila Healthcare Ltd. received restricted emergency use approval from the Drug Controller General of India for the use of ‘Virafin’, Pegylated Interferon alpha-2b, in treating moderate Covid-19 infections.
Considering the drug’s potential in reducing the need for supplemental oxygen and its better efficacy against other viral infections, we expect sales of Rs 2.5–3 billion on an annualized basis.
Accordingly, we raise our earnings estimates by 7%/6% for FY22/FY23, factoring in -
the Virafin opportunity and
lower operating cost in the domestic formulation segment on account of the lockdown.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.